Show simple item record

dc.contributor.authorThapa, Simant Singh
dc.contributor.authorLal, Amos
dc.contributor.authorÖmer, Abdulkadir
dc.contributor.authorTrivedi, Nitin
dc.date.accessioned2019-12-23T14:00:46Z
dc.date.available2019-12-23T14:00:46Z
dc.date.issued2019en_US
dc.identifier.citationThapa, S. S., Lal, A., Ömer, A. ve Trivedi, N. (2019). Elevated β-hydroxybutyric acid with no ketoacidosis in type 2 diabetic patients using sodium-glucose cotransporter-2 inhibitors. Journal of the Formosan Medical Association, 118(10), 1473-1474. https://doi.org/10.1016/j.jfma.2019.04.021en_US
dc.identifier.issn0929-6646
dc.identifier.urihttps://doi.org/10.1016/j.jfma.2019.04.021
dc.identifier.urihttps://hdl.handle.net/20.500.12511/4621
dc.description.abstractSGLT2 inhibitor (SGLT2i) class of medications are known to cause to euglycemic diabetic ketoacidosis (euDKA) as reported in the article by Lin et al. in your esteemed publication about this entity being reported for the first time in Taiwanese population.1 We wish to share the findings from our center to further expand the spectrum of findings associated with SGLT2i therapy. SGLT2i treatment in patients with preexisting atherosclerotic heart disease and those with high risk of cardiovascular events is associated with a reduction in cardiovascular (CV) mortality, heart failure hospitalizations, and death from any cause.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCardiovascularen_US
dc.subjectEuglycemic-Diabetic Ketoacidosisen_US
dc.subjectKetonemiaen_US
dc.subjectSGLT2en_US
dc.titleElevated β-hydroxybutyric acid with no ketoacidosis in type 2 diabetic patients using sodium-glucose cotransporter-2 inhibitorsen_US
dc.typearticleen_US
dc.relation.journalJournal of the Formosan Medical Associationen_US
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Rejeneratif ve Restoratif Tıp Araştırmaları Merkezi (REMER)en_US
dc.authorid0000-0003-2209-7694en_US
dc.identifier.volume118en_US
dc.identifier.issue10en_US
dc.identifier.startpage1473en_US
dc.identifier.endpage1474en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1016/j.jfma.2019.04.021en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess